Drones and Copper: How Canadian Biotech is Reshaping Frontline Trauma Care

TORONTO – October 28, 2026 — In the modern theater of war, the structural integrity of a nation is tested not just by the endurance of its electrical grids or the strength of its armor, but by the resilience of its medical supply chains. When the arteries of conventional logistics are severed by artillery and blockades, the state's ability to protect its citizens begins to fray. It is in these fractured spaces that innovation must bridge the gap between life and death.

Today, that bridge is being built by a Calgary-based biotechnology startup. NanoTess announced at the CAN Health Network Annual Conference that its flagship wound and burn care product, NanoSALV Catalytic, is currently being deployed to civilians and frontline soldiers in Ukraine. But it is the method of delivery—navigating the treacherous skies via drone—that underscores a radical shift in how we manage trauma in logistically compromised environments.

Working in collaboration with the Public Health Centre of Ukraine, the Medical Forces and Sustainment Group East, and the humanitarian organization Medical Mercy Canada, NanoTess has successfully distributed its proprietary treatment to more than 6,000 individuals. This deployment is more than a humanitarian victory; it is a forensic case study in how Canadian dual-use technology is reshaping the future of austere medicine.

The Logistics of Survival in Austere Environments

The Eastern Front of Ukraine is a logistical crucible. Traditional medical evacuation routes are frequently compromised, and the golden hour of trauma care is often stretched into agonizing days. In these conditions, heavy, temperature-sensitive medical supplies become liabilities.

NanoSALV Catalytic was engineered to bypass these very bottlenecks. Powered by NanoTess's proprietary Catalytic Treatment Matrix (CTM), the product is lightweight, environmentally stable, and non-flammable. These characteristics make it uniquely suited for drone delivery, allowing unmanned aerial vehicles to bypass destroyed roads and active fire to drop critical medical supplies directly into the hands of medics and soldiers.

Dr. Vasyl Voronets, a Military Surgeon operating in Ukraine's Eastern Front, has witnessed the operational advantage firsthand. "Effective medical treatment in active conflict zones and during recovery is critical to our soldiers," he says. "Burns require urgent care and complex blast wounds, typically sustained in drone strikes, are easily contaminated by debris and can quickly become infected. Antimicrobial-resistant bacteria can further complicate treatment, leading to prolonged hospital stays and recovery."

For Voronets and his teams, the environmental stability of the Canadian-made gel means it can be stockpiled in forward operating bases and delivered on demand. "We know these challenges all too well and have seen the toll they take on our troops, our operational capabilities, and the civilians we are working to protect," Voronets adds. "NanoSALV Catalytic has changed how we approach wound and burn care in the immediate aftermath of injury. It has helped us treat more people, more quickly, in extremely challenging conditions where environmental stability is essential."

Combatting the Invisible Enemy: Superbugs and Blast Trauma

While the logistics of drone delivery solve the problem of access, the biological reality of modern warfare presents a secondary, often more lethal, challenge: infection. Blast wounds are inherently dirty, driving debris deep into tissue, creating an ideal breeding ground for antimicrobial-resistant bacteria—the so-called superbugs that have become a silent epidemic in global conflict zones.

This is where the science of CTM becomes critical. The technology utilizes engineered copper structures to create a wound environment that regulates inflammation and promotes revascularization, granulation tissue formation, and remodeling. More importantly, it provides broad-spectrum antimicrobial effects without relying on traditional antibiotics, thereby circumventing the resistance mechanisms that render standard drugs ineffective.

Hailie Uren, Antimicrobial Resistance and Infection Control Research Lead with the Ministry of Health of Ukraine, emphasizes the urgency of this mechanism. "In Ukraine, time is everything," Uren explains. "A wound that might be manageable in a Canadian hospital can become life-threatening when evacuation is delayed, medical supplies are limited, and infection sets in. We need solutions that work in the realities of frontline care, not just in ideal clinical settings. What makes innovations like NanoSALV so important is the potential to get wound care into the hands of those who need it, when and where they need it most."

The clinical efficacy of the treatment is not merely anecdotal. Before its deployment in Ukraine, NanoSALV Catalytic underwent rigorous real-world evaluation in Canada. A project supported by the CAN Health Network involving Alberta Health Services demonstrated that the product significantly improved the healing of chronic wounds, showing a 57.6 percent area reduction over just four weeks, while simultaneously reducing wound care costs by nearly half.

Dr. Eric Fung, a Plastic and Reconstructive Surgeon with Alberta Health Services, recognized this potential early on. "While working in Ukraine, I brought NanoSALV with me because I had seen what this Canadian innovation could do for patients," Fung notes. "Working alongside medical teams on the ground, I experienced firsthand how difficult it can be to deliver care in these conditions. What struck me most was the dedication and resilience of the Ukrainian medical teams, who are doing extraordinary work with limited resources. Seeing a technology developed and proven here in Alberta now helping to save lives in Ukraine is something every Canadian should be proud of."

The Dual-Use Doctrine: From Battlefield to Bedside

The success of NanoTess in Ukraine is not a happy accident; it is the deliberate result of a shifting Canadian policy framework that recognizes the value of dual-use technology. For years, the intersection of civilian healthcare innovation and military application was treated as an afterthought. Today, it is a strategic imperative.

NanoTess's journey reflects this evolution. Founded in 2020 by Megan Leslie and Julian Mulia on social enterprise values, the company quickly caught the attention of the Department of National Defence. Through programs like Innovation for Defence Excellence and Security, the federal government provided early-stage funding to research and develop the CTM platform. Earlier this year, the Government of Canada awarded NanoTess a further investment grant specifically to expand the dual-use capabilities of CTM, including the development of alternative delivery methods for military health and recovery.

This funding strategy acknowledges a fundamental truth: the austere environments of the battlefield and the resource-strained realities of public healthcare often demand the same solutions. A wound care product that is portable, stable, and easy to use by personnel with limited medical training is just as valuable in a remote Indigenous community in Northern Canada as it is in a trench in Eastern Europe.

Megan Leslie, Co-Founder and CEO of NanoTess, views this dual application as a core responsibility. "Conflict zones present some of the most challenging conditions for wound and burn care, where injuries can be severe, resources stretched, and access to medical aid uncertain," Leslie says. "But in these challenging conditions there is an opportunity for innovation to make a real difference; to reduce suffering, preserve limbs, and save lives."

For Leslie, the deployment abroad is deeply connected to the mission at home. "We believe innovation carries a responsibility: to reach beyond the expected, overcome barriers to care, and bring solutions to the people and places where the need is greatest," she continues. "It also strengthens our commitment to advocating for vulnerable patients on home soil: seniors, people living with comorbidities and chronic health conditions, our unhoused population, and all those whose lives are disproportionately impacted by wounds and who continue to face barriers to accessing the care they need."

The Future of the Public Square

As we analyze the systems that hold our modern world together, the NanoTess deployment offers a compelling blueprint. It demonstrates how federal policy, by actively funding dual-use biotechnology, can foster innovations that protect the citizen both domestically and abroad.

Dr. Dante Morra, Founder and CEO of the CAN Health Network, summarizes the broader national imperative. "This is what happens when we believe in Canadian companies, back Canadian innovation, and give our entrepreneurs the opportunity to solve problems," he says. "We don't just build solutions for Canada. We build solutions the world needs. NanoTess should be on the shelves of every hospital and health care facility across this country, as it continues to demonstrate what Canadian innovation can achieve when we give it the opportunity to grow, scale, and change lives around the world."

Already, the domestic integration is accelerating. Authorized by Health Canada in 2022, NanoSALV Catalytic is now accessible across 2,500 healthcare facilities and 14,000 pharmacies nationwide. It has secured its place on the Alberta Drug Benefit List and Ontario Health at Home, proving that the technology can scale within the rigid structures of provincial health systems.

In an era where global infrastructure is increasingly fragile, the relationship between the citizen and the state relies on our capacity to adapt. By merging the tactical logistics of drone delivery with the advanced biochemistry of catalytic copper, Canada is not just exporting a medical device. It is exporting a resilient system—one capable of holding the line when everything else begins to fray.